Literature DB >> 19406951

Characterizing the effects of common UDP glucuronosyltransferase (UGT) 1A6 and UGT1A1 polymorphisms on cis- and trans-resveratrol glucuronidation.

Otito Frances Iwuchukwu1, Jumoke Ajetunmobi, Din Ung, Swati Nagar.   

Abstract

The dietary polyphenol resveratrol (RES) exists as cis- and trans-isomers with known stereospecific and stereoselective glucuronidation at the 3 and 4' positions by distinct UGT1A isoforms. We examined cis-RES glucuronidation in various protein sources. UGT1A6 or UGT1A1 genotype-dependent cis-or trans-RES glucuronidation, respectively, was further determined. cis-RES exhibited partial substrate inhibition in UGT1A6 Supersomes and human embryonic kidney 293 cells overexpressing genetically variant UGT1A6 alleles. Cells expressing UGT1A6*4 had the highest activity with a V(max) of 612 +/- 27.36 nmol/min/mg, followed by UGT1A6*3. The *2 allozyme had a higher V(max) (1.6-fold) and K(m) (1.9-fold) than *1. In 51 human liver samples genotyped for UGT1A6, four alleles (frequencies) were identified as *1 (0.58), *2 (0.36), *3 (0.01), and *4 (0.05), leading to assignment of the following genotypes (frequencies): *1/*1 (0.29), *1/*2 (0.45), *1/*3 (0.02), *1/*4 (0.10), and *2/*2 (0.14). Up to 5-fold variability in trans-RES glucuronidation was observed in individual liver samples. In livers stratified by UGT1A6 genotype, a significant difference in cis-RES glucuronidation activity (p < 0.05) was seen between the *2 variants compared with homozygous *1 livers. The trans-RES glucuronidation was quantitated in a human liver bank genotyped for the UGT1A1 TATA box repeat polymorphism. There was no significant difference for formation of trans-RES 3-O-glucuronide. We were surprised to find that trans-RES 4'-O-glucuronide formation was higher in livers with the 7/7 genotype compared with 6/6 and 6/7 (p < 0.05). In conclusion, cis-RES glucuronidation exhibited atypical partial substrate inhibition kinetics in vitro. Whereas cis-RES glucuronidation varied with UGT1A6 genotypes, the UGT1A1*28 polymorphism did not explain variability in trans-RES glucuronidation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19406951     DOI: 10.1124/dmd.109.027391

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  5 in total

1.  Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients.

Authors:  Xiao-Man Chu; Li-Fang Zhang; Guang-Ji Wang; Shen-Ning Zhang; Jia-Hui Zhou; Hai-Ping Hao
Journal:  Eur J Clin Pharmacol       Date:  2012-04-05       Impact factor: 2.953

2.  Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases.

Authors:  Krishna C Chimalakonda; Stacie M Bratton; Vi-Huyen Le; Kan Hui Yiew; Anna Dineva; Cindy L Moran; Laura P James; Jeffery H Moran; Anna Radominska-Pandya
Journal:  Drug Metab Dispos       Date:  2011-07-11       Impact factor: 3.922

3.  Bioavailability and molecular activities of anthocyanins as modulators of endothelial function.

Authors:  Antonio Speciale; Francesco Cimino; Antonella Saija; Raffaella Canali; Fabio Virgili
Journal:  Genes Nutr       Date:  2014-05-17       Impact factor: 5.523

Review 4.  Use of hiPSC to explicate genomic predisposition to anthracycline-induced cardiotoxicity.

Authors:  Tarek Magdy; Paul W Burridge
Journal:  Pharmacogenomics       Date:  2021-01-15       Impact factor: 2.533

Review 5.  Contribution of Biotransformations Carried Out by the Microbiota, Drug-Metabolizing Enzymes, and Transport Proteins to the Biological Activities of Phytochemicals Found in the Diet.

Authors:  Anna Boronat; Jose Rodriguez-Morató; Gabriele Serreli; Montserrat Fitó; Rachel F Tyndale; Monica Deiana; Rafael de la Torre
Journal:  Adv Nutr       Date:  2021-12-01       Impact factor: 11.567

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.